World's Best Scientists 2026 revealed!
François Ghiringhelli

François Ghiringhelli

D-Index & Metrics

Immunology

D-Index
104
Citations
60171
World Ranking
603
National Ranking
18

Medicine

D-Index
104
Citations
60251
World Ranking
6905
National Ranking
208

François Ghiringhelli publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where François Ghiringhelli sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 426 publications — 84th percentile

84% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

François Ghiringhelli D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where François Ghiringhelli sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 104 D-Index — 88th percentile

88% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

François Ghiringhelli is affiliated with Grenoble Alpes University in France and has conducted extensive research primarily in the field of Medicine, with a strong focus on Oncology, Pulmonary and Respiratory Medicine, Immunology, Molecular Biology, and Surgery. Their scholarly output reflects a multidisciplinary approach to cancer research and related biomedical sciences.

Their work spans several main topics, emphasizing:

  • Cancer Immunotherapy and Biomarkers
  • Colorectal Cancer Treatments and Studies
  • Cancer Genomics and Diagnostics
  • Immunotherapy and Immune Responses
  • Lung Cancer Treatments and Mutations
  • Pancreatic and Hepatic Oncology Research
  • Gastric Cancer Management and Outcomes

Ghiringhelli has published prolifically in journals such as:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Cancers
  • Cancer Research
  • European Journal of Cancer

A selection of recent publications includes:

  • Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer, 2022, Nature Medicine
  • Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophage, 2020, Science
  • Interleukin-1β and Cancer, 2020, Cancers
  • Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer, 2022, JAMA Oncology
  • Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts, 2020, European Journal of Cancer

Frequent collaborators in their research include:

  • Caroline Truntzer
  • Valentin Dérangère
  • Emeric Limagne
  • Romain Boidot
  • Christophe Borg

François Ghiringhelli's body of work contributes to advancing understanding in cancer immunotherapy, biomarker identification, and therapeutic strategies across various cancer types including lung, colorectal, pancreatic, and gastric cancers.

Best Publications

  • Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

    Bertrand Routy;Bertrand Routy;Bertrand Routy;Lisa Derosa;Lisa Derosa;Lisa Derosa;Connie P. M. Duong;Connie P. M. Duong

  • Calreticulin exposure dictates the immunogenicity of cancer cell death

    Michel Obeid;Antoine Tesniere;Antoine Tesniere;Antoine Tesniere;François Ghiringhelli;François Ghiringhelli;François Ghiringhelli;Gian Maria Fimia

  • Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.

    Lionel Apetoh;François Ghiringhelli;Antoine Tesniere;Antoine Tesniere;Antoine Tesniere;Michel Obeid;Michel Obeid;Michel Obeid

  • The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide

    Sophie Viaud;Sophie Viaud;Fabiana Saccheri;Grégoire Mignot;Takahiro Yamazaki

  • Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors

    François Ghiringhelli;Lionel Apetoh;Antoine Tesniere;Antoine Tesniere;Antoine Tesniere;Laetitia Aymeric;Laetitia Aymeric;Laetitia Aymeric

  • Immunological aspects of cancer chemotherapy.

    Laurence Zitvogel;Lionel Apetoh;Lionel Apetoh;François Ghiringhelli;Guido Kroemer;Guido Kroemer

  • Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death.

    Noelia Casares;Marie O. Pequignot;Antoine Tesniere;François Ghiringhelli

  • Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

    François Ghiringhelli;Cedric Menard;Pierre Emmanuel Puig;Sylvain Ladoire

  • Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice.

    Mickaël Michaud;Mickaël Michaud;Mickaël Michaud;Isabelle Martins;Isabelle Martins;Isabelle Martins;Abdul Qader Sukkurwala;Abdul Qader Sukkurwala;Abdul Qader Sukkurwala;Sandy Adjemian;Sandy Adjemian;Sandy Adjemian

  • 5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell–Dependent Antitumor Immunity

    Julie Vincent;Grégoire Mignot;Fanny Chalmin;Sylvain Ladoire

  • Immunogenic death of colon cancer cells treated with oxaliplatin.

    A. Tesniere;F. Schlemmer;F. Schlemmer;F. Schlemmer;V. Boige;O. Kepp;O. Kepp;O. Kepp

  • CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor–β–dependent manner

    Francois Ghiringhelli;Cédric Ménard;Magali Terme;Caroline Flament

  • CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative

    François Ghiringhelli;Nicolas Larmonier;Elise Schmitt;Arnaud Parcellier

  • Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells

    Fanny Chalmin;Sylvain Ladoire;Grégoire Mignot;Julie Vincent

  • Tumor cells convert immature myeloid dendritic cells into TGF-β–secreting cells inducing CD4+CD25+ regulatory T cell proliferation

    François Ghiringhelli;Pierre E. Puig;Stephan Roux;Arnaud Parcellier

  • Consensus guidelines for the detection of immunogenic cell death

    Oliver Kepp;Laura Senovilla;Ilio Vitale;Erika Vacchelli

  • Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth

    Mélanie Bruchard;Grégoire Mignot;Grégoire Mignot;Valentin Derangère;Valentin Derangère;Fanny Chalmin;Fanny Chalmin

  • The anticancer immune response: indispensable for therapeutic success?

    Laurence Zitvogel;Lionel Apetoh;François Ghiringhelli;Fabrice André

  • The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy.

    Lionel Apetoh;François Ghiringhelli;Antoine Tesniere;Antoine Tesniere;Antoine Tesniere;Alfredo Criollo;Alfredo Criollo;Alfredo Criollo

  • Classification of current anticancer immunotherapies

    Lorenzo Galluzzi;Erika Vacchelli;José Manuel Bravo-San Pedro;Aitziber Buqué

Frequent Co-Authors

Lionel Apetoh
Lionel Apetoh Indiana University
Guido Kroemer
Guido Kroemer Université Paris Cité
Antoine Tesniere
Antoine Tesniere Université Paris Cité
Christophe Borg
Christophe Borg Centre Hospitalier Universitaire de Besançon
Olivier Bouché
Olivier Bouché CHU de Reims
Julien Taieb
Julien Taieb Université Paris Cité
Laurence Zitvogel
Laurence Zitvogel University of Paris-Saclay
Oliver Kepp
Oliver Kepp Institut Gustave Roussy
Valérie Boige
Valérie Boige Institut Gustave Roussy
Theocharis Panaretakis
Theocharis Panaretakis The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, expanding into healthcare roles can open diverse career pathways. Many professionals pursue advanced nursing qualifications to work closely with immunological treatments and patient care. For instance, a nurse interested in quick advancement may consider a nurse practitioner accelerated program to gain specialized skills efficiently.

Individuals without a nursing background can also enter the field through accessible programs. The best online BSN programs for non nurses offer flexible routes for complete beginners to become registered nurses, complementing Immunology expertise with patient-focused knowledge.

Those seeking quicker entry into nursing may explore accelerated nursing programs, which allow faster onboarding into professional roles. Similarly, the healthcare system values licensed practical nurses (LPNs), and there are easy LPN programs to get into, offering accessible options for immediate hands-on experience.

By aligning studies in Immunology with these nursing pathways, students can build a strong foundation for careers in clinical research, patient care, or public health, maximizing impact in the evolving medical landscape.

Best Scientists Citing François Ghiringhelli

Trending Scientists

Recently Published Articles